IL2 and type 1 diabetes mellitus: In a study conducted by D’Addio and co-authors [82], it was shown that the SARS-CoV-2 mRNA vaccine may lead to a reduced cellular immune response specific to SARS-CoV-2, particularly in relation to IL2, in individuals with type 1 diabetes.